Implant Sciences/CardioTech
This article was originally published in The Gray Sheet
Executive Summary
Phase I Small Business Innovation Research Grant of $100,000 from NIH awarded to conduct research targeting improvements in drug delivery to abdominal aortic aneurysm (AAA) sites by incorporating heparin and rapamycin drugs into non-erodable, biodurable polyurethane graft coatings. Implant Sciences will provide a self-expanding, gold-coated Nitinol stent for improved radiopaque visualization, while CardioTech will contribute its ChronoFlex biodurable polyurethane loaded with rapamycin and coated with heparin. After a six-month trial is complete, an additional $750,000 Phase II grant may be available to develop the device into a commercial product...